Latest: FDA Approves New Biosimilar for Oncology Treatment
Pharmaceutical

Microbiotica completes recruitment for phase 1b ulcerative colitis trial

by PharmaTimes
0 Comments
0 Mins
MB310 study investigates safety and efficacy of precision microbiome therapy MB310 study investigates safety and efficacy of precision microbiome therapy
Tags:
PharmaTimes
Author

PharmaTimes

Previous Post
Monkeypox Virus Clade IIa Infections, Liberia, 2023–2024
Next Post
US$30.9 million strategic equity deal strengthens Everest’s oncology platform
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago